Close

Shionogi Inc announced availabilty of Kapvay

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.
Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider.

Related stories

X-Ray Crystallography Vs. Cryo-EM: Which Method Fits Your Research

X-ray crystallography usually fits best when you need fast,...

Why Successful Innovation Starts with the Right Resources

Every business wants to be innovative, but turning a...
- Advertisement -

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., announced a true milestone as it marks the first commercial availability for the noncentral nervous system stimulant medication KAPVAY, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

KAPVAY is the first and only FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication, in addition to use as monotherapy.

Donald C. Manning, MD, PhD, Chief Medical Officer of Shionogi Inc said, Shionogi is extremely proud to bring KAPVAY? to market in the U.S. The extended-release version of clonidine hydrochloride found in KAPVAY? offers an exciting new treatment option for children and adolescents with ADHD who are not experiencing adequate symptom relief from stimulants alone.

ADHD affects more than 4.5 million children in the U.S., with at least 7 percent of U.S. school-aged children believed to suffer from the condition. Symptoms include difficulty in maintaining attention and focus and in controlling behavior, as well as hyperactivity/over-activity. While stimulant medications remain a first line treatment for ADHD, up to 30 percent of ADHD patients do not achieve an optimal response to stimulant monotherapy.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

X-Ray Crystallography Vs. Cryo-EM: Which Method Fits Your Research

X-ray crystallography usually fits best when you need fast,...

Why Successful Innovation Starts with the Right Resources

Every business wants to be innovative, but turning a...

Körber Launches PAS-X Neo MES for Small Pharma Manufacturers

Technology company Körber has introduced a new manufacturing execution...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »